Compare LCTX & ASTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCTX | ASTL |
|---|---|---|
| Founded | 1990 | 1902 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Steel/Iron Ore |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.7M | 467.0M |
| IPO Year | 1996 | N/A |
| Metric | LCTX | ASTL |
|---|---|---|
| Price | $1.49 | $3.96 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $5.33 | N/A |
| AVG Volume (30 Days) | 1.2M | ★ 1.4M |
| Earning Date | 03-05-2026 | 03-11-2026 |
| Dividend Yield | N/A | ★ 1.20% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,556,000.00 | N/A |
| Revenue This Year | $55.75 | N/A |
| Revenue Next Year | $2.96 | $25.68 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 53.24 | N/A |
| 52 Week Low | $0.37 | $3.02 |
| 52 Week High | $2.09 | $7.25 |
| Indicator | LCTX | ASTL |
|---|---|---|
| Relative Strength Index (RSI) | 37.77 | 45.56 |
| Support Level | $0.94 | $3.54 |
| Resistance Level | $1.84 | $4.77 |
| Average True Range (ATR) | 0.09 | 0.28 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 15.91 | 54.03 |
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
Algoma Steel Group Inc is a fully integrated steel producer of hot and cold rolled steel products, including coiled sheet and plate, strategically located. The firm operates in a single segment of basic steel production including sheets, plates, slabs, and freights. The company's revenue is generated from contracts to produce, ship, and deliver steel products Geographically it serves Canada, the United States, and the rest of the world, whilst driving key revenue from domestic sales. The company generates the majority of its revenue from the sale of Steel sheets and strips.